Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pfenex Inc.PFNX · Entity 146052 | Chief Financial Officer | March 01, 2017 | March 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pfenex Inc.
Report date March 01, 2017 · Filed March 16, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.47 · Expires 2027-03-01 | Direct | 85,000 |
Reported balance
After 2017-03-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-03-01 · Grant · Acquired 85,000 · Balance 85,000 F1: 25% shall vest on the one year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2017. F2: This amendment is being filed to correct the expiration date of the Option. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% shall vest on the one year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2017.
F2: This amendment is being filed to correct the expiration date of the Option.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forte Biosciences, Inc.
Report date August 27, 2026 · Filed August 27, 2026
Section 16 reporting ended · disclosed 2026-08-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 1
1 source rowRow 1 · 2026-08-27 · Other · Disposed 85,482 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.50 · Expires 2028-12-19 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-27 · Disposition to issuer · Disposed 16,866 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $991.50 · Expires 2031-04-09 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-27 · Disposition to issuer · Disposed 5,400 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.00 · Expires 2032-01-17 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-27 · Disposition to issuer · Disposed 11,999 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.25 · Expires 2034-03-21 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-27 · Disposition to issuer · Disposed 44,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2035-03-20 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-27 · Disposition to issuer · Disposed 920,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.66 · Expires 2036-01-12 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-27 · Disposition to issuer · Disposed 270,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.15 · Expires 2036-06-16 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-27 · Disposition to issuer · Disposed 500,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-27 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-27 · Disposition to issuer · Disposed 180,000 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-27 · Disposition to issuer · Disposed 3,511 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2023 Filed Dec 15, 2023 23:29 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 10,000 | $0.72 | $7,200.00 |
DisclosureSEC source: 0001209191-23-058867 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,813,236 F2 · price: Represents the weighted average share price of an aggregate total of 10,000 shares purchased in the price range of $0.7199 to $0.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 23:29 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 10,520 | $0.70 | $7,351.38 |
DisclosureSEC source: 0001209191-23-058867 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,803,236 F1 · price: Represents the weighted average share price of an aggregate total of 10,520 shares purchased in the price range of $0.679 to $0.70 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 00:30 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 4,776 | $0.65 | $3,088.16 |
DisclosureSEC source: 0001209191-23-058404 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,792,716 F2 · price: Represents the weighted average share price of an aggregate total of 4,776 shares purchased in the price range of $0.639 to $0.65 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 00:30 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 25,000 | $0.65 | $16,187.50 |
DisclosureSEC source: 0001209191-23-058404 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,787,940 F1 · price: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $0.6199 to $0.65 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 08, 2023 Filed Dec 9, 2023 00:20 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 15,000 | $0.62 | $9,300.00 |
DisclosureSEC source: 0001209191-23-057989 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,762,940 F2 · price: Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $0.6085 to $0.62 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 07, 2023 Filed Dec 9, 2023 00:20 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 36,203 | $0.58 | $21,167.89 |
DisclosureSEC source: 0001209191-23-057989 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,747,940 F1 · price: Represents the weighted average share price of an aggregate total of 36,203 shares purchased in the price range of $0.54 to $0.60 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 22, 2023 Filed Nov 22, 2023 22:51 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 400 | $0.43 | $172.00 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 4 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,711,737 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:51 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 100 | $0.43 | $42.51 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,711,337 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:51 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 1,566 | $0.43 | $673.38 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,711,237 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:51 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 5,300 | $0.44 | $2,332.00 |
DisclosureSEC source: 0001209191-23-056522 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,709,671 Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:26 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051476 · doc4.xml · derivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,250 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:26 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Tax withholdingCommon Stock | 2,453 | $0.66 | $1,623.89 |
DisclosureSEC source: 0001209191-23-051476 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,371 F2 · price: On October 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on September 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:26 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051476 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,706,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:56 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantCommon Stock | 247,524 | $1.01 | $249,999.24 |
DisclosureSEC source: 0001209191-23-044280 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,675,574 Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:04 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-040961 · doc4.xml · derivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:04 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Tax withholdingCommon Stock | 2,453 | $1.04 | $2,551.12 |
DisclosureSEC source: 0001209191-23-040961 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,428,050 F2 · price: On July 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on June 30, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:04 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-040961 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,430,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:19 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023083 · doc4.xml · derivative · entry 3 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,750 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:19 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Tax withholdingCommon Stock | 11,046 | $1.01 | $11,156.46 |
DisclosureSEC source: 0001209191-23-023083 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,399,253 F2 · price: On April 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on March 31, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:19 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023083 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,410,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 20:17 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-020744 · doc4.xml · derivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:21 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 44,024 | $1.07 | $47,000.02 |
DisclosureSEC source: 0001209191-22-061903 · doc4.xml · nonDerivative · entry 2 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,379,049 F2 · price: Represents the weighted average share price of an aggregate total of 44,024 shares purchased in the price range of $1.03 to $1.09 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:21 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 55,976 | $1.03 | $57,672.07 |
DisclosureSEC source: 0001209191-22-061903 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335,025 F1 · price: Represents the weighted average share price of an aggregate total of 55,976 shares purchased in the price range of $1.00 to $1.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 12, 2022 Filed May 16, 2022 21:05 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Disposition to issuerStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $39.66 | $0.00 |
DisclosureSEC source: 0001209191-22-029214 · doc4.xml · derivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 40,000 shares Expires 2031-04-09 F1 · shares: 40,000 of the shares subject to this option were canceled by mutual agreement of the Reporting Person and the Issuer. F2 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2017 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 9, 2021. Read SEC document |
| January 17, 2022 Filed Jan 19, 2022 01:26 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0000899243-22-002261 · doc4.xml · derivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 17, 2022. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:02 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | SaleCommon Stock | 1,000,000 | $4.35 | $4,347,100.00 |
DisclosureSEC source: 0000899243-21-035344 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279,049 F1 · price: Represents the weighted average share price of an aggregate total of 1,000,000 shares sold in the price range of $4.1403 to $4.64 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 22:03 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $39.66 | $0.00 |
DisclosureSEC source: 0000899243-21-015641 · doc4.xml · derivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-04-09 F1 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 9, 2021. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 00:13 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | PurchaseCommon Stock | 7,000 | $14.48 | $101,355.80 |
DisclosureSEC source: 0001209191-20-039272 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279,049 F1 · price: Represents the weighted average share price of an aggregate total of 7,000 shares purchased in the price range of $14.1620 to $14.9899 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 17:08 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0000899243-17-006102 · doc4.xml · derivative · entry 1 Wagner Paul A. · CIK 0001612842 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2017-03-01 F1 · derivative.exercise_date: 25% shall vest on the one year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 16, 2017 18:18 UTC Amendment | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0000899243-17-007812 · doc4a.xml · derivative · entry 1 Wagner Paul A. · CIK 0001612842 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-03-01 F1 · derivative.exercise_date: 25% shall vest on the one year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2017. F2 · derivative.expiration_date: This amendment is being filed to correct the expiration date of the Option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.